Axillary dissection in sentinel lymph node positive breast cancer: Is the staging information worthwhile for patients?
David W Chang, Mathias Bressel, Carmen Hansen, Prunella Blinman, Penelope Schofield, Boon H Chua
Asia-Pacific Journal of Clinical Oncology | WILEY | Published : 2019
AIMS: The Z0011 randomized trial demonstrated no significant difference in axillary recurrence rate or survival with or without axillary dissection in patients with a positive sentinel node biopsy. However, there is continuing controversy regarding the generalizability of its results, and axillary dissection provides additional pathologic staging information that may guide adjuvant therapy. Thus, axillary dissection after positive sentinel node biopsy is being further investigated in an actively recruiting randomized trial. We elicited patients' preferences for axillary dissection versus no axillary dissection after positive sentinel node biopsy for early breast cancer. METHODS: Patients who..View full abstract